Photo of Kevin Elias,  MD

Kevin Elias, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-8840


kelias@bwh.harvard.edu

Kevin Elias, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
  • Director, Gynecologic Oncology Laboratory, Division of Gynecologic Oncology, Brigham And Women's Hospital

Research Abstract

My laboratory focuses on the prevention, diagnosis, and treatment of women with gynecologic cancers. Our group includes a mixture of gynecologic oncology fellows, post-doctoral PhDs, technicians, and support staff. The thrust of our work is devoted to the early diagnosis of ovarian cancer, novel treatment approaches based on polymer chemistry, and in vivo models of gynecologic malignancies, including choriocarcinoma and ovarian cancer.

Publications

Powered by Harvard Catalyst
  • Gockley AA, Elias KM. Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. Cancer Treat Rev 2018; 69:66-71. PubMed
  • Cramer DW, Elias KM. Perspectives on Ovarian Cancer From SEER: Today and Tomorrow. Journal of the National Cancer Institute 2018. PubMed
  • Braga A, Biscaro A, do Amaral Giordani JM, Viggiano M, Elias KM, Berkowitz RS, Seckl MJ. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? Eur J Obstet Gynecol Reprod Biol 2018; 223:50-55. PubMed
  • Padrón L, Rezende Filho J, Amim Junior J, Sun SY, Charry RC, Maestá I, Elias KM, Horowitz N, Braga A, Berkowitz RS. Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy. Obstet Gynecol 2018; 131:652-659. PubMed
  • Nitecki R, Berkowitz RS, Elias KM, Goldstein DP, Horowitz NS. Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know? Int J Gynecol Cancer 2018. PubMed
  • Dreaden EC, Kong YW, Quadir MA, Correa S, Suárez-López L, Barberio AE, Hwang MK, Shi AC, Oberlton B, Gallagher PN, Shopsowitz KE, Elias KM, Yaffe MB, Hammond PT. RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors. Bioeng Transl Med 2018; 3:26-36. PubMed
  • Maestá I, Nitecki R, Horowitz NS, Goldstein DP, de Freitas Segalla Moreira M, Elias KM, Berkowitz RS. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol 2018; 148:161-167. PubMed
  • Worley MJ, Elias KM, Horowitz NS, Quade BJ, Berkowitz RS. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol 2018; 148:5-11. PubMed
  • Braga A, Campos V, Filho JR, Lin LH, Sun SY, de Souza CB, da Silva RCAF, Leal EAS, Silveira E, Maestá I, Madi JM, Uberti EH, Viggiano M, Elias KM, Horowitz N, Berkowitz RS. Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? Gynecol Oncol 2017. PubMed
  • Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, Frendl G, Konstantinopoulos P, Crum CP, Kedzierska M, Cramer DW, Chowdhury D. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. Elife 2017. PubMed
  • Dantas PRS, Maestá I, Filho JR, Junior JA, Elias KM, Howoritz N, Braga A, Berkowitz RS. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? Gynecol Oncol 2017. PubMed
  • Elias KM. Understanding Enhanced Recovery After Surgery Guidelines: An Introductory Approach. 2017; 27:871-875. PubMed
  • Chung TKH, Cheung TH, Yim SF, Yu MY, Chiu RWK, Lo KWK, Lee IPC, Wong RRY, Lau KKM, Wang VW, Worley MJ, Elias KM, Fiascone SJ, Smith DI, Berkowitz RS, Wong YF. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Gynecol Oncol 2017. PubMed
  • Liu CY, Elias KM, Howitt BE, Lee LJ, Feltmate CM. Sentinel lymph node mapping reduces practice pattern variations in surgical staging for endometrial adenocarcinoma: A before and after study. Gynecol Oncol 2017. PubMed
  • Elias KM, Harvey RA, Hasselblatt KT, Seckl MJ, Berkowitz RS. Type I interferons modulate methotrexate resistance in gestational trophoblastic neoplasia. Am J Reprod Immunol 2017. PubMed
  • Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, MacDuffie E, Davis MR, Holman A, Lawney B, Freedman ML, Quackenbush J, Brown M, Drapkin R. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI Insight 2016. PubMed
  • Cramer DW, Elias KM. A prognostically relevant miRNA signature for epithelial ovarian cancer. Lancet Oncol. 2016; 17:1032-3. PubMed
  • Braga A, Maestá I, Soares RR, Elias KM, Domingues MA, Barbisan LF, Berkowitz RS. Apoptotic index for prediction of post-molar gestational trophoblastic neoplasia. Am J Obstet Gynecol 2016. PubMed
  • Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep 2016; 14:429-39. PubMed
  • Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecol Oncol 2015; 139:97-103. PubMed
  • Chung TK, Van Hummelen P, Chan PK, Cheung TH, Yim SF, Yu MY, Ducar MD, Thorner AR, MacConaill LE, Doran G, Pedamallu CS, Ojesina AI, Wong RR, Wang VW, Freeman SS, Lau TS, Kwong J, Chan LK, Fromer M, May T, Worley MJ, Esselen KM, Elias KM, Lawrence M, Getz G, Smith DI, Crum CP, Meyerson M, Berkowitz RS, Wong YF. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer 2015. PubMed
  • Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 2014. PubMed
  • Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-6. PubMed
  • Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM, O'Shea JJ. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008; 111:1013-20. PubMed
  • Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 2006; 96:1-22. PubMed
Hide